Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Colorectal Cancer Diagnostics Market Size & Share 2026-2035
Report ID: GMI6924
|
Published Date: October 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:
Colorectal Cancer Diagnostics Market
Get a free sample of this reportWhat are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.

Colorectal Cancer Diagnostics Market Size
The colorectal cancer diagnostics market was valued at USD 14.50 billion in 2025 and is projected to reach USD 15.80 billion in 2026, advancing at an 8.0% CAGR (2026-2035) to attain USD 31.30 billion by 2035.
Colorectal Cancer Diagnostics Market Key Takeaways
Market Leader: Exact Sciences led with over 16.8% market share in 2025.
Leading Players: Top 5 players in this market include Exact Sciences, Olympus Corporation, Boston Scientific, Siemens Healthineers, Roche Diagnostics, which collectively held a market share of 45.2% in 2025.
The colorectal cancer diagnostics market combines an established revenue base in endoscopy and pathology with a widening non-invasive testing layer spanning stool-based and blood-based approaches. This evolution expands access to screening while retaining the downstream procedural and tissue-confirmation pathways that support diagnostic spending across the patient journey.
GMI Analyst View
Our engagement with supply-chain participants and review of available manufacturer-level revenue data indicate that the colorectal cancer diagnostics market stood at USD 10.20 billion in 2022, which underscores the substantial commercial momentum the sector has built over the historic period as non-invasive testing adoption, AI-assisted endoscopy integration, and guideline-driven screening expansion collectively widened the revenue base heading into the current forecast cycle.
Colorectal Cancer Diagnostics Market Trends, Growth Drivers & GMI Forecast Outlook
Demand is being shaped by the interaction of a growing screening-eligible population, policy-led access expansion, and technology that adds software and service revenue to conventional diagnostic workflows. Forecast realization depends on whether reimbursement, clinical adoption, and follow-up capacity keep pace with broader screening availability.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Disease burden broadens demand not only for initial screening but also for staging, surveillance, lesion characterization, and follow-up testing. The commercial effect is strongest where screening systems can move patients efficiently from a preliminary result to confirmatory colonoscopy, biopsy, pathology, and molecular assessment.
The screening-age expansion changes the economics of market access by moving a previously underserved cohort into reimbursed pathways. Manufacturers with accessible sample collection, established payer relationships, and primary-care distribution are positioned to benefit first, while endoscopy suppliers gain from the referral activity generated when non-invasive tests identify patients requiring further investigation.
CADe integration alters the endoscopy value proposition by making clinical decision support part of the installed-base relationship. As adoption progresses beyond tertiary settings, software, service, and workflow integration can increase revenue intensity without relying solely on replacement cycles for capital equipment.
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Screening eligibility does not automatically become completed testing. Preparation concerns, limited awareness of available modalities, inconsistent primary-care recommendations, and constrained follow-up access can suppress utilization even when screening is reimbursed and clinically recommended.
Access disparities create a second friction point because the cost and logistics of diagnostic follow-up remain material barriers for underserved populations. The resulting gap concentrates realized demand in better-insured pathways and makes payer design, outreach, and referral infrastructure important determinants of volume conversion.
Blood-based screening adds convenience at the point of collection, but a positive result still initiates an endoscopic diagnostic pathway. Its near-term market role is therefore additive rather than fully substitutive, particularly while next-generation assays seek to improve performance for pre-cancerous lesions.
GMI Analyst View
We see a transitional demand structure in which established endoscopy and pathology revenue continues to benefit from procedural volume, while non-invasive testing moves into broader reimbursed use. The central market-mix effect is layering: a positive non-invasive result can create downstream colonoscopy and biopsy demand rather than displacing it.
Colorectal Cancer Diagnostics Market Segment Analysis
By Test Type
The colorectal cancer diagnostics market's blood-based liquid biopsy segment generated USD 220 million in 2025 and is projected to reach USD 3.10 billion by 2035. Commercial scaling depends on converting regulatory access into routine primary-care ordering, strengthening payer coverage, and improving the clinical utility of assays for patients with pre-cancerous lesions.
Stool-based tests were valued at USD 2.90 billion in 2025 and are projected to reach USD 5.60 billion by 2035. At-home collection and established reimbursement support their role as an accessible entry point into screening, while positive results continue to create referral demand for colonoscopy and pathology services.
Imaging & endoscopy accounted for 52.0% of market revenue in 2025 and are projected to reach USD 15.00 billion by 2035. The segment remains anchored by colonoscopy's clinical role in detection and intervention, with AI-assisted detection, accessories, consumables, and service arrangements broadening revenue beyond core equipment sales.
Biopsy & pathology is projected to advance at a 7.2% CAGR (2026-2035) and reach USD 5.80 billion by 2035. Its position reflects the need for tissue confirmation and biomarker characterization, while digital pathology and molecular workflows increase the efficiency and clinical relevance of laboratory testing.
Other diagnostics generated USD 940 million in 2025 and are expected to advance at a 6.7% CAGR (2026-2035). This category serves as an innovation channel for complementary technologies, with longer-term commercial adoption dependent on clinical validation, guideline acceptance, and reimbursement.
By End Use
Hospitals generated USD 7.98 billion in 2025 and are projected to reach USD 15.65 billion by 2035. Their concentration of endoscopy suites, oncology services, pathology laboratories, and complex patient pathways preserves a leading role in diagnostic purchasing and integrated care delivery.
Diagnostic imaging centers generated USD 3.63 billion in 2025 and are advancing at an 8.8% CAGR (2026-2035). Outpatient migration supports their growth as providers seek efficient settings for imaging and procedure-based diagnostics, although referral relationships and access to follow-up services remain important competitive differentiators.
Cancer research institutes are projected to reach USD 2.50 billion by 2035 and maintain an 8.0% revenue share. Their demand centers on specialized molecular and translational applications, where research workflows can influence subsequent clinical adoption of advanced diagnostic platforms.
Others are projected to advance at a 10.4% CAGR (2026-2035) and reach USD 4.70 billion by 2035. Primary-care clinics, pharmacy-based programs, and telehealth-enabled pathways extend screening beyond hospital settings, particularly where non-invasive collection models reduce patient friction.
GMI Analyst View
We view the diagnostic pathway as cumulative rather than competitive. Non-invasive tests can broaden screening participation, but positive findings lead to endoscopy, biopsy, and molecular pathology activity. Suppliers with exposure across these linked steps are better positioned to capture value from a single patient episode.
Colorectal Cancer Diagnostics Market Regional Analysis
North America Colorectal Cancer Diagnostics Market Analysis
The colorectal cancer diagnostics market in North America was valued at USD 6.38 billion in 2025 and is projected to reach USD 12.00 billion by 2035. Mature colonoscopy infrastructure, broad diagnostic capability, and policy-supported screening underpin demand, while newer non-invasive modalities add to rather than replace established procedural pathways.
U.S.
The U.S. generated USD 5.55 billion in 2025 and is projected to reach USD 10.35 billion by 2035. Its scale reflects extensive screening infrastructure, strong commercial payer participation, and a large installed base for endoscopy, pathology, and molecular diagnostics.
Canada
Canada generated USD 830 million in 2025 and is advancing at a 7.1% CAGR (2026-2035). Provincial screening programs and publicly funded care pathways support sustained demand for FIT-based testing and endoscopy services, although procurement and adoption can vary by province.
Europe Colorectal Cancer Diagnostics Market Analysis
Europe is projected to reach USD 6.20 billion by 2035 and accounted for 22.0% of global market revenue in 2025. National screening programs provide a recurring demand floor across the region, while differences in reimbursement, organized screening participation, and diagnostic capacity shape the pace of modality adoption.
Germany
Germany accounted for 21.9% of European revenue in 2025 and is projected to reach USD 1.34 billion by 2035. Its established screening infrastructure supports demand across colonoscopy, stool-based testing, pathology, and molecular workflows.
UK
The UK generated USD 570 million in 2025 and is advancing at a 7.0% CAGR (2026-2035). Structured national screening pathways support consistent FIT volumes and maintain a dependable stream of referrals for diagnostic colonoscopy.
France
France is projected to reach USD 1.02 billion by 2035 and represented 16.0% of European market revenue in 2025. Organized screening provides a platform for population-level test distribution, with diagnostic conversion dependent on participation and follow-up capacity.
Italy
Italy generated USD 380 million in 2025 and is advancing at a 6.4% CAGR (2026-2035). Regional variation in organized screening rollout creates uneven demand conditions, but broader program implementation supports continued diagnostic market development.
Spain
Spain is projected to reach USD 590 million by 2035 and accounted for 10.0% of European market revenue in 2025. Regional management of screening programs makes local implementation capability important to the pace of testing and referral growth.
Asia Pacific Colorectal Cancer Diagnostics Market Analysis
Asia Pacific generated USD 3.77 billion in 2025 and is projected to reach USD 10.00 billion by 2035. Expanding hospital capacity, rising molecular diagnostics adoption, and investment in early detection programs create a growth environment in which installed-base development and screening access advance together.
China
China generated USD 1.43 billion in 2025 and is projected to reach USD 3.89 billion by 2035. The market's development is supported by a large screening opportunity and expanding access to hospital-based endoscopy, pathology, and cancer diagnostics.
Japan
Japan generated USD 830 million in 2025 and is advancing at a 9.5% CAGR (2026-2035). Its mature diagnostic infrastructure and established cancer-screening culture support continued uptake across both procedural and laboratory-based testing pathways.
India
India is projected to reach USD 1.48 billion by 2035 and is advancing at an 11.7% CAGR (2026-2035). Expanding urban hospital networks and broader investment in early cancer detection support demand, although affordability and uneven access remain relevant market constraints.
Australia
Australia accounted for 8.0% of Asia Pacific market revenue in 2025 and is projected to reach USD 720 million by 2035. Its organized screening environment supports predictable demand for stool-based testing and downstream diagnostic procedures.
South Korea
South Korea is projected to reach USD 870 million by 2035 and is advancing at a 9.8% CAGR (2026-2035). High endoscopy capacity and a developed hospital system support the adoption of advanced diagnostic technologies alongside population-screening activity.
Latin America Colorectal Cancer Diagnostics Market Analysis
Latin America generated USD 730 million in 2025 and is advancing at a 9.5% CAGR (2026-2035). Rising disease awareness, growing private-sector healthcare access, and gradual expansion of diagnostic capacity underpin market development, although coverage disparities continue to influence utilization.
Brazil
Brazil generated USD 330 million in 2025 and is advancing at a 9.4% CAGR (2026-2035). Demand is supported by private healthcare coverage and the gradual expansion of colonoscopy and molecular diagnostic access across major urban markets.
Mexico
Mexico accounted for 27.4% of Latin American revenue in 2025 and is projected to reach USD 510 million by 2035. Healthcare infrastructure investment and growing private-sector demand are expanding the commercially accessible screening population.
Argentina
Argentina contributes modestly to regional demand, with private healthcare access in urban centers supporting gradual uptake of colorectal cancer diagnostic technologies.
Middle East & Africa Colorectal Cancer Diagnostics Market Analysis
Middle East & Africa is projected to reach USD 1.30 billion by 2035 and advance at an 11.6% CAGR (2026-2035). Growth is being driven by investment in hospital infrastructure, rising diagnostic service availability, and the early-stage penetration of organized screening and advanced laboratory capabilities.
Saudi Arabia
Saudi Arabia generated USD 100 million in 2025 and is advancing at a 12.0% CAGR (2026-2035). Hospital-network expansion and investment in diagnostic service capacity are strengthening access to gastroenterology and oncology testing.
UAE
The UAE is projected to reach USD 240 million by 2035 and accounted for 18.2% of Middle East & Africa revenue in 2025. High healthcare spending and a sizeable private hospital sector support demand for advanced imaging, endoscopy, and laboratory diagnostics.
South Africa
South Africa generated USD 70 million in 2025 and is advancing at a 10.5% CAGR (2026-2035). Private hospital investment in gastroenterology and oncology capabilities supports diagnostic growth, although access remains uneven across care settings.
GMI Analyst View
We see a clear divergence between mature markets, where product-mix premiumization drives incremental value, and developing markets, where endoscopy capacity and laboratory infrastructure are still being built. Broad geographic coverage gives manufacturers greater exposure to both installed-base expansion and advanced-modality adoption.
Colorectal Cancer Diagnostics Market Share & Competitive Landscape
The colorectal cancer diagnostics market share structure is moderately concentrated at the top, with the five leading suppliers collectively accounting for approximately 45.2% of global revenue in 2025. Competition remains active across endoscopy systems, pathology reagents, molecular testing, imaging, stool-based screening, and emerging liquid-biopsy platforms, leaving substantial room for specialists and infrastructure suppliers.
Exact Sciences held a 16.8% revenue share in 2025, supported by its stool DNA screening franchise and related commercial reach. Its agreement for exclusive U.S. rights to Freenome's blood-based colorectal cancer screening tests brings an upfront payment of USD 75 million and potential milestones of up to USD 700 million, strengthening its participation in a developing non-invasive testing category [5]Exact Sciences Corporation / Freenome. "Exact Sciences Announces Exclusive License with Freenome for Blood-Based Colorectal Cancer Screening Tests." businesswire.com.
Olympus held an 11.5% revenue share in 2025, reflecting its position in colonoscopy and flexible endoscopy equipment. Its competitive relevance extends beyond capital equipment through recurring consumables, procedural tools, service arrangements, and AI-assisted workflow offerings.
Abbott's planned acquisition of Exact Sciences would combine a leading cancer-screening franchise with a global diagnostics commercial platform. The transaction has an equity value of approximately USD 21 billion and enterprise value of approximately USD 23 billion, with an expected close in the second quarter of 2026 [6]Exact Sciences Corporation. "Abbott to Acquire Exact Sciences, a Leader in Large and Fast-Growing Cancer Screening and Precision Diagnostics." exactsciences.com.
Guardant Health's Shield blood test introduces a new primary-care-oriented screening pathway, but its positioning is shaped by the continuing need for confirmatory diagnostic procedures after positive findings. In the ECLIPSE study, Shield demonstrated 83% sensitivity for colorectal cancer and 90% specificity across approximately 8,000 participants [4]National Cancer Institute. "Colorectal Cancer Screening: Where Does the Shield Liquid Biopsy Fit In?" cancer.gov.
Roche, Siemens Healthineers, GE HealthCare, QIAGEN, Danaher, Thermo Fisher Scientific, Sysmex, and H.U. Group contribute through diagnostic infrastructure, imaging, laboratory instruments, pathology workflows, and molecular testing capabilities. DiaCarta, New Day Diagnostics, Phase Scientific International, and Geneoscopy represent specialist and emerging competitors seeking to differentiate through assay design, decentralized access, or novel biomarker approaches.
Recent Industry Developments
Abbott's acquisition of Exact Sciences (November 2025). Abbott and Exact Sciences announced a definitive agreement for Abbott to acquire Exact Sciences, with the transaction expected to close in the second quarter of 2026. The proposed combination would pair Exact Sciences' cancer-screening portfolio with Abbott's global diagnostics infrastructure [6]Exact Sciences Corporation. "Abbott to Acquire Exact Sciences, a Leader in Large and Fast-Growing Cancer Screening and Precision Diagnostics." exactsciences.com.
Exact Sciences secures exclusive rights to Freenome's blood-based colorectal cancer screening tests (August 2025). Exact Sciences announced an exclusive U.S. license for current and future Freenome blood-based colorectal cancer screening tests. The agreement expands Exact Sciences' access to non-invasive screening technologies as blood-based modalities seek broader clinical and reimbursement adoption [5]Exact Sciences Corporation / Freenome. "Exact Sciences Announces Exclusive License with Freenome for Blood-Based Colorectal Cancer Screening Tests." businesswire.com.
Geneoscopy closes Series C financing for ColoSense commercialization (January 2025). Geneoscopy closed a USD 105 million Series C financing round led by Bio-Rad Laboratories to support the launch of its ColoSense stool-RNA screening test through a Labcorp partnership [7]Bio-Rad Laboratories / Geneoscopy. "Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests." investors.bio-rad.com.
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →